Internal Medicine, Endocrinology, Diabetes, & Metabolism · Eastvale, CA
NPI
1730543752
Since 2016
Specialty
Internal Medicine, Endocrinology, Diabetes, & Metabolism
Code 207RE0101X
Group practices
1
Medicare group memberships
Hospitals
0
Hospital affiliations
12742 Limonite Ave
Eastvale, CA, 92880
Phone (951) 739-2717
Groups this clinician bills Medicare through
Medicare paid, 2024
$37K
533 services
Medicare patients, 2024
105
Average age 72
Drug cost, 2024
$1.4M
3,069 prescriptions
Company payments, 2025
$727
From 10 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Manita Choudhary was code 99214 (office e&m - established), 157 times for 73 patients. In total Manita Choudhary billed 533 services in 17 codes, and Medicare paid $37K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2025-04-11.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 157 | 73 | $92.29 | $14K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 149 | 84 | $12.52 | $1,866 |
| 95251 Test - Miscellaneous | Office | 65 | 25 | $26.39 | $1,716 |
| 99215 Office E&M - Established | Office | 64 | 47 | $136.91 | $8,762 |
| 99205 Office E&M - New | Office | 33 | 33 | $167.87 | $5,540 |
By year: 2022 $13K for 125 services; 2023 $25K for 322 services; 2024 $37K for 533 services.
Medicare prescription drug claims, 2024
In 2024, the drug Manita Choudhary prescribed most often to Medicare patients was Ozempic (Semaglutide), with 333 prescriptions and refills. In total Manita Choudhary wrote 3,069 Medicare prescriptions that cost $1.4M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Ozempic Semaglutide | 333 | 433 | 72 | $394K |
| Jardiance Empagliflozin | 254 | 383 | 54 | $219K |
| Levothyroxine Sodium Generic | 215 | 547 | 57 | $2,832 |
| Metformin Hcl Generic | 213 | 566 | 67 | $2,144 |
| Lantus Solostar Insulin Glargine,hum.Rec.Anlog | 184 | 415 | 66 | $25K |
| Glipizide Generic | 164 | 402 | 50 | $1,419 |
| Atorvastatin Calcium Generic | 146 | 370 | 53 | $1,871 |
| Mounjaro Tirzepatide | 128 | 138 | 26 | $140K |
| Farxiga Dapagliflozin Propanediol | 100 | 148 | 21 | $79K |
| Nano 2nd Gen Pen Needle Pen Needle, Diabetic | 98 | 239 | 44 | $9,624 |
| Trulicity Dulaglutide | 97 | 126 | 20 | $122K |
| Lyumjev Kwikpen U-100 Insulin Lispro-Aabc | 82 | 131 | 21 | $80K |
| Synjardy Xr Empagliflozin/Metformin Hcl | 48 | 127 | 19 | $71K |
| Lisinopril Generic | 46 | 101 | 16 | $203 |
| Synthroid Levothyroxine Sodium | 45 | 117 | 15 | $2,486 |
Brand drugs: 1,656 claims; generic drugs: 1,162 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Manita Choudhary $727 ($727 in general payments such as food, travel and fees) from 10 companies. The largest payer was Lilly USA, LLC with $179.
| Company | Payments | Amount |
|---|---|---|
| Lilly USA, LLC LLY | 13 | $179 |
| Amgen Inc. AMGN | 9 | $138 |
| Tandem Diabetes Care, Inc. TNDM | 5 | $107 |
| Sequel Med Tech, LLC | 2 | $86.91 |
| Novo Nordisk Inc NVO | 3 | $64.78 |
| Abbott Laboratories ABT | 3 | $48.62 |
| Merck Sharp & Dohme LLC MRK | 2 | $36.71 |
| Rhythm Pharmaceuticals, Inc. RYTM | 1 | $23.94 |
| Corcept Therapeutics CORT | 1 | $23.81 |
| Medtronic, Inc. MDT | 1 | $18.04 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.